Current understanding of ELF4 deficiency: a novel inborn error of immunity.

World J Pediatr

Department of Rheumatology & Immunology, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Children's Hospital of Chongqing Medical University, Zhongshan Er Road 136Yuzhong District, Chongqing, China.

Published: May 2024

AI Article Synopsis

  • ELF4 deficiency is a newly identified immune disorder causing issues like recurrent oral ulcers, abdominal pain, and diarrhea, especially in boys.
  • The diagnosis involves genetic testing for variations in the ELF4 gene and confirming its impact through lab techniques like Western blotting.
  • Treatment mainly includes glucocorticoids and biologics, with the need for more patient data to refine and improve treatment strategies.

Article Abstract

Background: ELF4 deficiency has been recently recognized as a novel disorder within the spectrum of inborn errors of immunity (IEIs), specifically categorized as a "disease of immune dysregulation." Cases of this condition, reported by our team and others, are very limited worldwide. As such, our current knowledge of this new disease remains preliminary. This review aims to provide a brief overview of the clinical manifestations, pathogenesis, and treatment strategies for this novel IEI.

Data Sources: A comprehensive review was conducted after an extensive literature search in the PubMed/Medline database and websites concerning transcriptional factor ELF4 and reports concerning patients with ELF4 deficiency. Our search strategy was "ELF4 OR ETS-related transcription factor Elf-4 OR EL4-like factor 4 OR myeloid Elf-1-like factor" as of the time of manuscript submission.

Results: The current signature manifestations of ELF4 deficiency disorder are recurrent and prolonged oral ulcer, abdominal pain, and diarrhea in pediatric males. In some cases, immunodeficiency and autoimmunity can also be prominent. Targeted Sanger sequencing or whole exome sequencing can be used to detect variation in ELF4 gene. Western blotting for ELF4 expression of the patient's cells can confirm the pathogenic effect of the variant. To fully confirm the pathogenicity of the variant, further functional test is strongly advised. Glucocorticoid and biologics are the mainstream management of ELF4 deficiency disorder.

Conclusions: Pediatric males presenting with recurring ulcerations in digestive tract epithelium with or without recurrent fever should be suspected of DEX. When atypical presentations are prominent, variations in ELF4 gene should be carefully evaluated functionally due to the complex nature of ELF4 function. Experience of treating DEX includes use of glucocorticoid and biologics and more precise treatment needs more patients to identify and further mechanistic study.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12519-024-00807-0DOI Listing

Publication Analysis

Top Keywords

elf4 deficiency
20
elf4
10
pediatric males
8
elf4 gene
8
glucocorticoid biologics
8
deficiency
5
current understanding
4
understanding elf4
4
deficiency novel
4
novel inborn
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!